Giant fold gastritis induced by epoprostenol infusion in patients with pulmonary arterial hypertension

Yohei Miura, Masaharu Kataoka, Tomohiro Chiba, Takumi Inami, Hideaki Yoshino, Toru Satoh

Research output: Contribution to journalArticle

Abstract

Background: Epoprostenol infusion is the strongest and most convincing therapeutic strategy for severe pulmonary arterial hypertension (PAH). This study investigated the gastrointestinal side effects of epoprostenol. Methods and Results: The study group of 12 patients treated with epoprostenol (epoprostenol group) and 4 patients without epoprostenol (control group) underwent stomach barium examination, which revealed that the prevalence of giant fold gastritis was significantly higher in the patients treated with epoprostenol (75% in epoprostenol group vs. 0% in control group; P=0.019). Conclusions: Giant fold gastritis may be an important side effect of epoprostenol infusion.

Original languageEnglish
Pages (from-to)2676-2677
Number of pages2
JournalCirculation Journal
Volume82
Issue number10
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Gastritis
Epoprostenol
Pulmonary Hypertension
Control Groups
Barium
Stomach

Keywords

  • Epoprostenol
  • Giant fold gastritis
  • Pulmonary arterial hypertension
  • Stomach barium examination

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Giant fold gastritis induced by epoprostenol infusion in patients with pulmonary arterial hypertension. / Miura, Yohei; Kataoka, Masaharu; Chiba, Tomohiro; Inami, Takumi; Yoshino, Hideaki; Satoh, Toru.

In: Circulation Journal, Vol. 82, No. 10, 01.01.2018, p. 2676-2677.

Research output: Contribution to journalArticle

Miura, Y, Kataoka, M, Chiba, T, Inami, T, Yoshino, H & Satoh, T 2018, 'Giant fold gastritis induced by epoprostenol infusion in patients with pulmonary arterial hypertension', Circulation Journal, vol. 82, no. 10, pp. 2676-2677. https://doi.org/10.1253/circj.CJ-18-0349
Miura, Yohei ; Kataoka, Masaharu ; Chiba, Tomohiro ; Inami, Takumi ; Yoshino, Hideaki ; Satoh, Toru. / Giant fold gastritis induced by epoprostenol infusion in patients with pulmonary arterial hypertension. In: Circulation Journal. 2018 ; Vol. 82, No. 10. pp. 2676-2677.
@article{b792d4c102a14206b13ec04860decf98,
title = "Giant fold gastritis induced by epoprostenol infusion in patients with pulmonary arterial hypertension",
abstract = "Background: Epoprostenol infusion is the strongest and most convincing therapeutic strategy for severe pulmonary arterial hypertension (PAH). This study investigated the gastrointestinal side effects of epoprostenol. Methods and Results: The study group of 12 patients treated with epoprostenol (epoprostenol group) and 4 patients without epoprostenol (control group) underwent stomach barium examination, which revealed that the prevalence of giant fold gastritis was significantly higher in the patients treated with epoprostenol (75{\%} in epoprostenol group vs. 0{\%} in control group; P=0.019). Conclusions: Giant fold gastritis may be an important side effect of epoprostenol infusion.",
keywords = "Epoprostenol, Giant fold gastritis, Pulmonary arterial hypertension, Stomach barium examination",
author = "Yohei Miura and Masaharu Kataoka and Tomohiro Chiba and Takumi Inami and Hideaki Yoshino and Toru Satoh",
year = "2018",
month = "1",
day = "1",
doi = "10.1253/circj.CJ-18-0349",
language = "English",
volume = "82",
pages = "2676--2677",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "10",

}

TY - JOUR

T1 - Giant fold gastritis induced by epoprostenol infusion in patients with pulmonary arterial hypertension

AU - Miura, Yohei

AU - Kataoka, Masaharu

AU - Chiba, Tomohiro

AU - Inami, Takumi

AU - Yoshino, Hideaki

AU - Satoh, Toru

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Epoprostenol infusion is the strongest and most convincing therapeutic strategy for severe pulmonary arterial hypertension (PAH). This study investigated the gastrointestinal side effects of epoprostenol. Methods and Results: The study group of 12 patients treated with epoprostenol (epoprostenol group) and 4 patients without epoprostenol (control group) underwent stomach barium examination, which revealed that the prevalence of giant fold gastritis was significantly higher in the patients treated with epoprostenol (75% in epoprostenol group vs. 0% in control group; P=0.019). Conclusions: Giant fold gastritis may be an important side effect of epoprostenol infusion.

AB - Background: Epoprostenol infusion is the strongest and most convincing therapeutic strategy for severe pulmonary arterial hypertension (PAH). This study investigated the gastrointestinal side effects of epoprostenol. Methods and Results: The study group of 12 patients treated with epoprostenol (epoprostenol group) and 4 patients without epoprostenol (control group) underwent stomach barium examination, which revealed that the prevalence of giant fold gastritis was significantly higher in the patients treated with epoprostenol (75% in epoprostenol group vs. 0% in control group; P=0.019). Conclusions: Giant fold gastritis may be an important side effect of epoprostenol infusion.

KW - Epoprostenol

KW - Giant fold gastritis

KW - Pulmonary arterial hypertension

KW - Stomach barium examination

UR - http://www.scopus.com/inward/record.url?scp=85054087253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054087253&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-18-0349

DO - 10.1253/circj.CJ-18-0349

M3 - Article

VL - 82

SP - 2676

EP - 2677

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 10

ER -